With ongoing advances in science and technology, the cell and gene therapy pipeline has grown especially robust over the past few years. At present, ClinicalTrials.gov shows more than 4,500 active gene therapy trials globally. In the United States, McKinsey experts expect to see 10 to 20 cell and gene therapy approvals per year over the next five years.
This rise in supply has created a heightened demand for contract development and manufacturing organizations (CDMOs) with bioprocessing expertise. CDMOs typically supply materials and handle production and manufacturing, allowing biotech companies to focus on innovation and marketing.
In an article published by BioPharmaDive, Emergent experts discuss the factors to consider when selecting your next CDMO partner to support your gene therapy drug candidates.
